{
    "eid": "2-s2.0-85073434270",
    "title": "Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: A prospective multicenter study",
    "cover-date": "2019-10-16",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Genetics",
            "@code": "1311",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "High risked neuroblastoma",
        "Induction therapy",
        "Prognostic factor",
        "Topotecan",
        "Treatment response",
        "Treatment-related toxicity"
    ],
    "authors": [
        "Piya Rujkijyanont",
        "Apichat Photia",
        "Chanchai Traivaree",
        "Chalinee Monsereenusorn",
        "Usanarat Anurathapan",
        "Panya Seksarn",
        "Darintr Sosothikul",
        "Piti Techavichit",
        "Kleebsabai Sanpakit",
        "Kamon Phuakpet",
        "Surapon Wiangnon",
        "Thirachit Chotsampancharoen",
        "Su On Chainansamit",
        "Somjai Kanjanapongkul",
        "Arunotai Meekaewkunchorn",
        "Suradej Hongeng"
    ],
    "citedby-count": 9,
    "ref-count": 38,
    "ref-list": [
        "Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use",
        "Neuroblastoma: Molecular pathogenesis and therapy",
        "The international neuroblastoma risk group (INRG) classification system: An INRG task force report",
        "Advances in risk classification and treatment strategies for neuroblastoma",
        "Recent advances in neuroblastoma",
        "Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): An international, randomised, multi-arm, open-label, phase 3 trial",
        "Advances in neuroblastoma therapy",
        "Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study",
        "Topotecan in the first-line treatment of small cell lung cancer",
        "Update on the role of topotecan in the treatment of non-small cell lung cancer",
        "Topotecan in the treatment of recurrent small cell lung cancer: An update",
        "Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric oncology group phase II study",
        "Phase i study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric oncology group study",
        "Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: Results of a phase 2 trial",
        "Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: Short-term curative effects and toxicity",
        "Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma",
        "Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's oncology group study",
        "A topotecan-containing induction regimen for treatment of high risk neuroblastoma",
        "Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's oncology group study",
        "Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma",
        "A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study",
        "Neuroblastoma: Biology, prognosis, and treatment",
        "Overview and recent advances in the treatment of neuroblastoma",
        "Neuroblastoma: A review of management and outcome",
        "Management of neuroblastoma: ICMR consensus document",
        "Revisions to the international neuroblastoma response criteria: A consensus statement from the National Cancer Institute clinical trials planning meeting",
        "Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment",
        "The effects of health care reforms on health inequalities: A review and analysis of the European evidence base",
        "Health systems performance and cancer outcomes",
        "Overview of supportive care in patients receiving chemotherapy: Antiemetics, pain management, anemia, and neutropenia",
        "Inequity in cancer care: Explanations and solutions for disparity",
        "Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers",
        "Impact of treatment site in adolescents and young adults with central nervous system tumors",
        "Adolescents and young adults with acute lymphoblastic Leukemia and acute myeloid Leukemia: Impact of Care at Specialized Cancer Centers on survival outcome",
        "Impact of care at comprehensive cancer centers on outcome: Results from a population-based study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60012921",
            "affilname": "Khon Kaen Regional Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012921",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60010778",
            "affilname": "Queen Sirikit National Institute of Child Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010778",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60006964",
            "affilname": "Phramongkutklao College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006964",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Maha Sarakham",
            "@id": "60002875",
            "affilname": "Mahasarakham University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002875",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Children Cancer Fund",
        "Patronage of Her Royal Highness Princess Soamsawali"
    ]
}